Lippis Daniel J. 4

What Happened
Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences (EW), exercised 1,019 derivative shares and immediately sold the 1,019 resulting common shares. The exercise recorded a cost basis of $59.26 per share (total $60,383). The open-market sale of those 1,019 shares occurred at a weighted-average price of $85.38, generating proceeds of about $87,004. Overall this looks like an option exercise followed by an immediate sale (cashless-style outcome).

Key Details

• Transaction date: March 11, 2026. Transaction codes: M = option exercise/conversion; S = open-market sale.
• Exercise: 1,019 shares at $59.26 each (total $60,383).
• Sale: 1,019 shares at weighted-average $85.38 each (total ~$87,004); executions ranged $85.16–$85.76 per footnote.
• Shares owned after transaction: Not disclosed in this Form 4 (filing notes it reflects changes only).
• Notable footnotes: Trades were made under a Rule 10b5-1 trading plan adopted July 30, 2025; seller can supply trade-by-trade detail on request per the filing.
• Filing timeliness: Reported on March 11, 2026 (same date as transactions), so appears timely.

Context
This filing shows an exercise of derivative awards (options/other convertible instruments) and an immediate sale of the acquired shares—commonly a routine cashless exercise and sale to cover the exercise cost, taxes, or diversify. The presence of a pre-established 10b5-1 plan means the sale was executed according to a previously adopted trading plan rather than being a discretionary, contemporaneous trade. This action is factual reporting of ownership change and does not by itself indicate the insider’s view of the company.